Lung cancer and colon cancer treated with epidermal growth factor receptor inhibitors
Conditions
Interventions
None listed
Sponsors
Oita University Faculty Of Medicine Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.The study is initially limited to patients with adenocarcinoma in lung and colon. 2.All patients are required to be treated with a single agent of EGFR-TKI (gefitinib, erlotinib,afatinib) or EGFR-Ab (cetuximab, panitumumab). 3.Skin damage has to recover to <= Grade 1 or can be distinguish from the adverse effect of prior therapies 4.An Eastern Co- operative Oncology Group performance status of 0, 1 or 2. 5.All patients had adequate hepatic, renal, and bone marrow function. 6.All patients were required to give informed consent.
Exclusion criteria
Exclusion criteria: 1.Patients had a medical history of treatment with gefitinib, erlotinib,afatinib, cetuximab, or panitumumab. 2.The patient has received systemic chemotherapy within 21 days or therapeutic radiation therapy within 14 days prior to the first dose of study therapy. Palliative radiation is permitted. 3.Patients have severe complications, as active infection and poorly controlled diabetes. 4.Patients has allergy, which is expected to interrupt the study. 5.Pregnant women 6.Multiple primary cancer. 7.Patients regularly use corticosteroids and immunosuppressive drugs. Inhalation and topical use are permitted.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relevance between Treg distribution in skin/circulation and progression free survival | — |
Countries
Japan
Contacts
Public ContactKazuo Nishikawa
Oita University Faculty Of Medicine Graduate School of Medicine Department of Medical Oncology & Hematology
Outcome results
None listed